Skip to main content
Erschienen in: Endocrine Pathology 1/2013

01.03.2013

Recurrent Acute-Onset Cushing’s Syndrome 6 Years after Removal of a Thymic Neuroendocrine Carcinoma: From Ectopic ACTH to CRH

verfasst von: Camilla Schalin-Jäntti, Sylvia L. Asa, Johanna Arola, Timo Sane

Erschienen in: Endocrine Pathology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

We describe a rare case of ectopic Cushing’s syndrome that recurred 6 years after resection of a thymic neuroendocrine carcinoma. We discuss reasons for the differing clinical presentations, management, hormone profiles, as well as immunopathology. A 41-year-old male developed acute-onset Cushing’s syndrome. Clinical presentation and laboratory results were compatible with ectopic adrenocorticotropin hormone (ACTH) production. Computerized tomography (CT) showed a 3.6 cm thymic tumor which was successfully resected. Plasma ACTH (P-ACTH) normalized the first postoperative day. Histopathology demonstrated a well-differentiated neuroendocrine carcinoma with diffuse positivity for ACTH and focal corticotropin-releasing hormone (CRH) reactivity in a few scattered cells. The patient was in remission for 6 years. He then again presented with acute-onset Cushing’s syndrome. Fluorine-labeled dihydroxyphenylalanine (18F-DOPA) PET/CT showed local uptake in the mediastinum and he underwent repeat resection. However, P-ACTH remained increased (613 ng/l) and 24-h urinary cortisol was 36,720 nmol, suggesting incomplete tumor removal or metastatic spread. Metyrapone treatment was initiated but then withdrawn because the patient spontaneously recovered and cortisol metabolism gradually normalized within 3 weeks. Histopathology demonstrated a recurrent neuroendocrine carcinoma with the same features as the previous lesion but this time CRH was strongly positive in more numerous cells. Normalization of P-ACTH after primary surgery was compatible with ectopic ACTH production. However, the delayed fall in P-ACTH and serum cortisol is compatible with ectopic CRH production and stimulation of pituitary ACTH secretion, which gradually resolved. Although ectopic CRH production is very rare, the unusual dynamics illustrated here should raise the possibility of CRH production by a neuroendocrine tumor.
Literatur
1.
Zurück zum Zitat Alexandraki KI, Grossman AB. The ectopic ACTH syndrome. Rev Endocr Metab Disord 11:117–126, 2010.PubMedCrossRef Alexandraki KI, Grossman AB. The ectopic ACTH syndrome. Rev Endocr Metab Disord 11:117–126, 2010.PubMedCrossRef
2.
Zurück zum Zitat Torpy DJ, Mullen N, Ilias I, Nieman LK. Association of hypertension and hypokalemia with Cushing’s syndrome caused by ectopic ACTH secretion. Ann NY Acad Sci 970:134–144, 2007.CrossRef Torpy DJ, Mullen N, Ilias I, Nieman LK. Association of hypertension and hypokalemia with Cushing’s syndrome caused by ectopic ACTH secretion. Ann NY Acad Sci 970:134–144, 2007.CrossRef
3.
Zurück zum Zitat Isidori AM, Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek H, Jenkins PJ, Monson JP, Grossman AB, Besser GM. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab 91:371–377, 2006.PubMedCrossRef Isidori AM, Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek H, Jenkins PJ, Monson JP, Grossman AB, Besser GM. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab 91:371–377, 2006.PubMedCrossRef
4.
Zurück zum Zitat Doi M, Sugiyama T, Izumiyama H, Yoshimoto T, Hirata Y. Clinical features and management of ectopic ACTH syndrome at a single institute in Japan. Endocr J 57:1061–1069; 2010.PubMedCrossRef Doi M, Sugiyama T, Izumiyama H, Yoshimoto T, Hirata Y. Clinical features and management of ectopic ACTH syndrome at a single institute in Japan. Endocr J 57:1061–1069; 2010.PubMedCrossRef
5.
Zurück zum Zitat Shahani S, Nudelman RJ, Nalini R, Kim H-S, Samson SL. Ectopic corticotropin-releasing hormone (CRH) syndrome from metastatic small cell carcinoma: a case report and review of the literature. Diagn Pathol 5:56, 2010.PubMedCrossRef Shahani S, Nudelman RJ, Nalini R, Kim H-S, Samson SL. Ectopic corticotropin-releasing hormone (CRH) syndrome from metastatic small cell carcinoma: a case report and review of the literature. Diagn Pathol 5:56, 2010.PubMedCrossRef
6.
Zurück zum Zitat Asa SL, Kovacs K, Vale W, Petrusz P, Vecsei P. Immunohistologic localization of corticotrophin-releasing hormone in human tumors. Am J Clin Pathol 87:327–333, 1987.PubMed Asa SL, Kovacs K, Vale W, Petrusz P, Vecsei P. Immunohistologic localization of corticotrophin-releasing hormone in human tumors. Am J Clin Pathol 87:327–333, 1987.PubMed
7.
Zurück zum Zitat Schteingart DE, Lloyd RV, Akil H, Chandler WF, Ibarra-Perez G, Rosen SG, Ogletree R. Cushing’s syndrome secondary to ectopic corticotrophin-releasing hormone-adrenocorticotropin secretion. J Clin Endocrinol Metab 63:770–775, 1986.PubMedCrossRef Schteingart DE, Lloyd RV, Akil H, Chandler WF, Ibarra-Perez G, Rosen SG, Ogletree R. Cushing’s syndrome secondary to ectopic corticotrophin-releasing hormone-adrenocorticotropin secretion. J Clin Endocrinol Metab 63:770–775, 1986.PubMedCrossRef
8.
Zurück zum Zitat Park SY, Rhee Y, Youn JC, Park YN, Lee S, Kim DM, Song SY, Lim S-K. Ectopic Cushing’s syndrome due to concurrent corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) secreted by malignant gastrinoma. Exp Clin Endocrinol Diabetes 144:444–447, 2007. Park SY, Rhee Y, Youn JC, Park YN, Lee S, Kim DM, Song SY, Lim S-K. Ectopic Cushing’s syndrome due to concurrent corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) secreted by malignant gastrinoma. Exp Clin Endocrinol Diabetes 144:444–447, 2007.
9.
Zurück zum Zitat Markou A, Manning P, Kaya B, Datta SN, Bomanji JD, Conway GS. [18F]fluoro-2-deoxy-d-glucose ([18F]FDG) positron emission tomography imaging of thymic carcinoid tumor presenting with recurrent Cushing’s syndrome. Eur J Endocrinol 152:521–525, 2005.PubMedCrossRef Markou A, Manning P, Kaya B, Datta SN, Bomanji JD, Conway GS. [18F]fluoro-2-deoxy-d-glucose ([18F]FDG) positron emission tomography imaging of thymic carcinoid tumor presenting with recurrent Cushing’s syndrome. Eur J Endocrinol 152:521–525, 2005.PubMedCrossRef
10.
Zurück zum Zitat Neary M, Lopez-Chavez A, Abel BS, Boyce AM, Schaub N, Kwong K, Stratakis CA, Moran CA, Giaccone G, Nieman LK (2012) Neuroendocrine ACTH-producing tumor of the thymus—experience with 12 patients over 25 years. J Clin Endocrinol Metab 97(7): 223–2230CrossRef Neary M, Lopez-Chavez A, Abel BS, Boyce AM, Schaub N, Kwong K, Stratakis CA, Moran CA, Giaccone G, Nieman LK (2012) Neuroendocrine ACTH-producing tumor of the thymus—experience with 12 patients over 25 years. J Clin Endocrinol Metab 97(7): 223–2230CrossRef
11.
Zurück zum Zitat Marx A, Shimosato Y, Kuo TT, Chan JKC, Travis WD, Wick MR. Thymic neuroendocrine tumours. In: Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, eds. World Health Organization Classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press:188–195, 2004. Marx A, Shimosato Y, Kuo TT, Chan JKC, Travis WD, Wick MR. Thymic neuroendocrine tumours. In: Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, eds. World Health Organization Classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press:188–195, 2004.
12.
Zurück zum Zitat Kauhanen S, Seppänen M, Ovaska J, Minn H, Bergman J, Korsoff P, Salmela P, Saltevo J, Sane T, Välimäki M, Nuutila P. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer 16:255–265, 2009.PubMedCrossRef Kauhanen S, Seppänen M, Ovaska J, Minn H, Bergman J, Korsoff P, Salmela P, Saltevo J, Sane T, Välimäki M, Nuutila P. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer 16:255–265, 2009.PubMedCrossRef
13.
Zurück zum Zitat Moran CA, Suster S. Neuroendocrine carcinomas (carcinoid tumor) of the thymus. Am J Clin Pathol 114:100–110, 2000.PubMedCrossRef Moran CA, Suster S. Neuroendocrine carcinomas (carcinoid tumor) of the thymus. Am J Clin Pathol 114:100–110, 2000.PubMedCrossRef
14.
Zurück zum Zitat Eriksson B, Örlefors H, Öberg K, Sundin A, Bergström M, Långström B. Developments in PET for the detection of endocrine tumors. Best Pract Res Clin Endocrinol Metab 19:311–324, 2005.PubMedCrossRef Eriksson B, Örlefors H, Öberg K, Sundin A, Bergström M, Långström B. Developments in PET for the detection of endocrine tumors. Best Pract Res Clin Endocrinol Metab 19:311–324, 2005.PubMedCrossRef
15.
Zurück zum Zitat Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastropancreatic neuroendocrine tumors: a meta-analysis. Endocrine 42:80–87, 2012.PubMedCrossRef Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastropancreatic neuroendocrine tumors: a meta-analysis. Endocrine 42:80–87, 2012.PubMedCrossRef
16.
Zurück zum Zitat Öberg K. Gallium-68 somatostatin receptor PET/CT: is it time to replace [111]Indium DTPA octreotide for patients with neuroendocrine tumors? Endocrine 42:3–4, 2012.PubMedCrossRef Öberg K. Gallium-68 somatostatin receptor PET/CT: is it time to replace [111]Indium DTPA octreotide for patients with neuroendocrine tumors? Endocrine 42:3–4, 2012.PubMedCrossRef
17.
Zurück zum Zitat Schalin-Jäntti C, Ahonen A, Seppänen M. F-18-DOPA PET/CT but not Ga-68-DOTA-TOC PET/CT revealed the underlying cause of ectopic Cushing’s syndrome. Clin Nucl Med 37:904–905, 2012.PubMedCrossRef Schalin-Jäntti C, Ahonen A, Seppänen M. F-18-DOPA PET/CT but not Ga-68-DOTA-TOC PET/CT revealed the underlying cause of ectopic Cushing’s syndrome. Clin Nucl Med 37:904–905, 2012.PubMedCrossRef
18.
Zurück zum Zitat Sugiura H, Morikawa T, Itoh K, Ono K, Okushiba S, Kondo S. Katoh H. Thymic neuroendocrine carcinoma: a clinicopathologic study in four patients. Ann Thorac Cardiovasc Surg 6:304–308, 2000.PubMed Sugiura H, Morikawa T, Itoh K, Ono K, Okushiba S, Kondo S. Katoh H. Thymic neuroendocrine carcinoma: a clinicopathologic study in four patients. Ann Thorac Cardiovasc Surg 6:304–308, 2000.PubMed
Metadaten
Titel
Recurrent Acute-Onset Cushing’s Syndrome 6 Years after Removal of a Thymic Neuroendocrine Carcinoma: From Ectopic ACTH to CRH
verfasst von
Camilla Schalin-Jäntti
Sylvia L. Asa
Johanna Arola
Timo Sane
Publikationsdatum
01.03.2013
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 1/2013
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-012-9228-5

Weitere Artikel der Ausgabe 1/2013

Endocrine Pathology 1/2013 Zur Ausgabe

Neu im Fachgebiet Pathologie